No person-to-person spread has been detected, but that doesn’t mean an H5N1 avian influenza pandemic isn’t possible or even ...

"We remain focused on our three strategic priorities: driving sales growth, delivering up to 10 product approvals over the ...

The latest funding is a sign of how seriously the Biden administration appears to be taking the pandemic threat.

Moderna has been testing an mRNA candidate for influenza viruses like the H5 and H7 strains that are seen as pandemic threats ...

As Moderna (NASDAQ: MRNA) looks to shore up its business in the wake of its declining coronavirus vaccine sales, it's natural ...

While the headline numbers don't inspire much confidence, Moderna is a stock that deserves a closer look. The company still ...

Robert F. Kennedy Jr. petitioned the FDA to revoke authorization of the shots when they were in high demand and thousands of ...

Annemarie Hanekamp has overseen some of the most transformative changes in oncology over her years in Big Pharma. Now, she ...

At the healthcare conference, Moderna lowered expected 2025 revenue to the range of $1.5 billion to $2.5 billion -- down from ...

Rare instances of vaccine side-effects must not be used to “undermine the vital public health role that vaccination plays in ...

Moderna provided updates on key elements of its pipeline, including a next-generation COVID-19 vaccine, an RSV vaccine, a new ...

MODERNA cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow adoption of its respiratory syncytial virus (RSV) ...